Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Stock Has Average Target Price of $18.12 According to Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has been given a consensus rating of “Buy” by the nine analysts that are currently covering the stock, Marketbeat reports. One analyst has rated the stock with a sell rating, six have assigned a buy rating and two have assigned a strong buy rating to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $18.12.

A number of equities analysts have issued reports on the stock. Chardan Capital raised shares of Lexeo Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 28th. JPMorgan Chase & Co. cut their price target on shares of Lexeo Therapeutics from $12.00 to $9.00 and set an “overweight” rating on the stock in a research report on Thursday, June 25th. Leerink Partners reiterated an “outperform” rating and issued a $15.00 target price on shares of Lexeo Therapeutics in a research note on Wednesday, September 23rd. Wall Street Zen raised Lexeo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Saturday, September 19th. Finally, Weiss Ratings raised Lexeo Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Thursday, August 13th.

Institutional Trading of Lexeo Therapeutics

Several institutional investors have recently added to or reduced their stakes in LXEO. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics during the 4th quarter valued at about $37,000. Legal & General Group Plc bought a new position in shares of Lexeo Therapeutics in the second quarter worth about $32,000. ProShare Advisors LLC purchased a new position in shares of Lexeo Therapeutics during the 4th quarter valued at about $146,000. Spark Investment Management LLC purchased a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at about $70,000. Finally, Canada Pension Plan Investment Board bought a new position in shares of Lexeo Therapeutics during the 2nd quarter valued at approximately $86,000. 60.67% of the stock is currently owned by institutional investors.

Lexeo Therapeutics Stock Down 2.5%

NASDAQ:LXEO opened at $3.53 on Tuesday. The firm has a market capitalization of $289.64 million, a price-to-earnings ratio of -3.07 and a beta of 1.63. The stock has a fifty day simple moving average of $4.43 and a 200 day simple moving average of $5.00. Lexeo Therapeutics has a 1-year low of $2.98 and a 1-year high of $10.99.

Lexeo Therapeutics (NASDAQ:LXEO) last posted its quarterly earnings results on Wednesday, August 12th. The company reported ($0.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.29) by ($0.01). Equities analysts predict that Lexeo Therapeutics will post -1.18 earnings per share for the current year.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc (NASDAQ:LXEO) is a clinical-stage biotechnology company developing genetic medicines for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other gene therapy technologies to deliver genetic material intended to address underlying causes of disease, with a focus on conditions affecting the central nervous system and cardiovascular system.

Lexeo’s pipeline includes LX2006, an investigational gene therapy being developed for Friedreich’s ataxia cardiomyopathy, a potentially life-threatening cardiac complication of Friedreich’s ataxia.